Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Dec 15;46(1):11.
doi: 10.1007/s00296-025-06016-w.

Effectiveness and cost-effectiveness of a multimodal, physiotherapist-led, vocational intervention for people with rheumatoid arthritis or axial spondyloarthritis and a reduced work ability: a randomized, controlled trial

Affiliations
Randomized Controlled Trial

Effectiveness and cost-effectiveness of a multimodal, physiotherapist-led, vocational intervention for people with rheumatoid arthritis or axial spondyloarthritis and a reduced work ability: a randomized, controlled trial

N F Bakker et al. Rheumatol Int. .

Abstract

To evaluate the (cost-)effectiveness of a physiotherapist-led, multimodal vocational intervention compared to usual care in adults with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA) experiencing reduced work ability. (Self-)employed people with RA or axSpA and reduced work ability were randomized to a 12-month vocational intervention or usual care. Assessments were conducted at baseline, 3, 6, and 12 months. Primary outcome was the Work Ability index Single-item Scale (WAS) at 12 months. Secondary outcomes included additional work-related and clinical outcomes. Cost-effectiveness was evaluated using the EuroQol to estimate quality-adjusted life years (QALYs), alongside healthcare use and productivity data. Primary analyses followed an intention-to-treat approach. A total of 140 participants (80 RA, 60 axSpA) were randomized 1:1 to the intervention or control group. At 12 months, the intervention showed no significant benefits over usual care on the WAS (estimated mean difference (MD): 0.40, 95% confidence interval (CI): - 0.22, 1.01) or any of the secondary outcomes. The QALYs were in favor of the intervention group by 0.05. The mean intervention costs were €395 per participant (90% usage, mean 9.5 sessions). After 12 months, the societal costs were €4324 lower in the intervention group (95% CI €-8169, €-479), mainly due to higher medication and presenteeism costs in the control group. At a willingness-to-pay threshold of €20.000/QALY, the intervention had a 99% probability of being cost-effective compared to usual care. While the intervention did not affect work ability in individuals with RA or axSpA, it outperformed usual care from a health-economic perspective, demonstrating its cost-effectiveness and potential value. International Clinical Trial Registry Platform (ICTRP) registration link: ICTRP Search Portal.

Keywords: Axial spondyloarthritis; Cost-utility; Physical therapy modalities; Randomized controlled trial; Rheumatoid arthritis; Vocational rehabilitation.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: N.F. Bakker, J. Knoop, W. B. van den Hout, N. Hutting, J.A. Engels, J.B. Staal, M. van der Leeden, A. Willemze, M.T. Nurmohamed, T.P.M. Vliet Vlieland, M.G.J. Gademan and S.F.E. van Weely declare that they have no conflict of interest. A. Boonen received research grants from Abbvie and Lilly, and honoraria for lectures or consultation from Pfizer, Novartis, UCB, Abbvie and Galapagos; all to her department. Ethical approval: to conduct the study was obtained on the 22th of July 2021 from the Medical Ethics Committee Leiden The Hague Delft (P21.050). This study was conducted in agreement with the declaration of Helsinki and in compliance with the General Data Protection Regulations and the Dutch Medical Research Involving Human Subjects Act. All participants provided written informed consent for their participation. The study protocol was included in the International Clinical Trial Registry Platform (ICTRP) under number NL-OMON26117 (ICTRP Search Portal). Open access publishing note: This article is published under an open access license and is freely available to the public. Readers are permitted to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author, provided proper citation is given. Related Congress abstract publication: This study was selected by the European Alliance of Associations for Rheumatology (EULAR) Congress 2025 (11–14 June) for an oral abstract presentation. The congress abstract was online published by EULAR: Bakker NF, van Weely SFE, Hutting N, Heerkens YF, Engels JA, Staal JB, van der Leeden M, Boonen A, van den Hout WB, Vliet Vlieland TPM, Knoop J. Effectiveness and cost-effectiveness of a multimodal, physiotherapist-led, vocational intervention in people with inflammatory arthritis: study protocol of the Physiotherapy WORKs trial. BMC Rheumatol. 2023 Sep 20;7(1):31. doi: https://doi.org/10.1186/s41927-023-00357-4 .

References

    1. Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73–84 - PubMed
    1. Black RJ, Cross M, Haile LM et al (2023) Global, regional, and National burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021. Lancet Rheumatol 5(10):e594–e610
    1. Uhlig T, Moe RH, Kvien TK (2014) The burden of disease in rheumatoid arthritis. PharmacoEconomics 32:841–851 - PubMed
    1. Nikiphorou E, Ramiro S (2020) Work disability in axial spondyloarthritis. Curr Rheumatol Rep 22:1–8
    1. Xavier RM, Zerbini CAF, Pollak DF et al (2019) Burden of rheumatoid arthritis on patients’ work productivity and quality of life. Adv Rheumatol 59(1):47 - PubMed

Publication types

MeSH terms

LinkOut - more resources